Ironwood Pharmaceuticals reported $225.99M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Akebia Therapeutics USD 220.78M 8.77M Sep/2026
Almirall EUR 747.1M 33.12M Jun/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amarin USD 612.88M 10.12M Sep/2026
Ardelyx USD 441.39M 538K Sep/2026
Astellas Pharma JPY 1.44T 41.22B Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Charles River Laboratories USD 1.54B 5.92M Sep/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Ironwood Pharmaceuticals USD 225.99M 26.79M Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
MacroGenics USD 295.08M 26.61M Sep/2026
Moderna USD 7.34B 1.53B Sep/2026
Myriad Genetics USD 289M 23.8M Jun/2026
Pacira USD 10.3B 9.68B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Takeda JPY 3T 153.11B Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025